10-K: Rallybio Pivots with Candid Merger, Focuses on CVRs

Rallybio Corporation announces a definitive merger agreement with Candid Therapeutics, shifting its strategic focus to T-cell engager therapeutics and monetizing legacy assets through Contingent Value Rights.

Summary

• Rallybio Corporation entered into a definitive Merger Agreement with Candid Therapeutics, Inc. on March 1, 2026, to become a wholly-owned subsidiary of Rallybio, with Candid's business continuing as the combined company.
• The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
• Concurrent with the merger agreement, Candid secured approximately $505.5 million in a Concurrent Financing from certain investors.
• Post-merger, pre-Merger equityholders of Candid (excluding Concurrent Financing investors) are expected to own approximately 57.55% of the combined company, Rallybio's pre-Merger equityholders approximately 3.65%, and Concurrent Financing investors approximately 38.80%.
• Rallybio's pre-Merger equityholders will receive one Contingent Value Right (CVR) for each outstanding Rallybio security, entitling them to a pro rata share of net proceeds from the disposition of Rallybio's pre-Merger assets (Legacy Assets) and cash proceeds from Recursion Pharmaceuticals, Inc. under a July 2025 Membership Interest Purchase Agreement.
• Rallybio will use commercially reasonable efforts for one year after the closing date to dispose of Legacy Assets.
• The company completed a confirmatory Phase 1 clinical trial for RLYB116 in healthy volunteers in 2025, demonstrating significant tolerability improvement and complete, sustained inhibition of terminal complement.
• RLYB116 is a once-weekly, small volume, subcutaneously injected C5 inhibitor with potential for multiple complement-mediated diseases like immune platelet transfusion refractoriness (PTR) and antiphospholipid syndrome (APS).
• RLYB332, a long-acting MTP-2 antibody for iron overload diseases (e.g., beta thalassemia, MDS), is in preclinical development, with favorable preclinical data presented in Q4 2024.
• Rallybio discontinued its RLYB212 program for FNAIT prevention in April 2025 due to pharmacokinetic data from a Phase 2 trial showing an inability to achieve target concentrations for efficacy.
• In July 2025, Rallybio sold its interest in REV102, an ENPP1 inhibitor, to a Recursion subsidiary for $20.0 million ($7.5 million upfront, $12.5 million milestone), with eligibility for a $5.0 million Phase 1 milestone payment and low single-digit royalties.
• Net loss for the year ended December 31, 2025, was $9.0 million, a significant improvement from $57.8 million in 2024, primarily due to a $23.0 million gain from the JV Sale.
• Research and development expenses decreased by $21.9 million to $19.6 million in 2025, mainly due to the discontinuation of the RLYB212 program and reduced RLYB116 manufacturing costs.
• General and administrative expenses decreased by $5.3 million to $14.3 million in 2025, driven by lower headcount and professional fees, partially offset by severance expenses from a May 2025 workforce reduction.
• Cash, cash equivalents, and marketable securities totaled $54.7 million as of December 31, 2025, projected to fund operations into 2028, assuming the merger completes in 2026.
• A 1-for-8 reverse stock split was effected on February 6, 2026, to regain compliance with Nasdaq's minimum bid price requirement, which was achieved by February 24, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary, but challenging, strategic pivot. While the merger provides a path forward and significant new capital for Candid's pipeline, it comes at the cost of substantial dilution for existing Rallybio shareholders and the discontinuation of a key program, reflecting underlying difficulties in Rallybio's standalone development.

Positives

• RLYB116's confirmatory Phase 1 trial achieved key objectives, demonstrating significant tolerability improvement and complete, sustained inhibition of terminal complement, supporting its potential as a best-in-class therapeutic.
• The sale of the REV102 program generated $20.0 million in cash proceeds in 2025, with potential for an additional $5.0 million milestone payment and low single-digit royalties.
• Net loss significantly decreased to $9.0 million in 2025 from $57.8 million in 2024, largely due to the gain from the JV Sale.
• Cash, cash equivalents, and marketable securities of $54.7 million as of December 31, 2025, are expected to fund operating expenses and capital requirements into 2028, assuming the merger completes.
• Successful 1-for-8 reverse stock split and subsequent regaining of Nasdaq compliance for the minimum bid price requirement.

Negatives

• The RLYB212 program for FNAIT prevention was discontinued in April 2025 due to insufficient pharmacokinetic data to achieve target concentrations for efficacy.
• Rallybio's pre-Merger equityholders will experience substantial dilution, owning only approximately 3.65% of the combined company post-merger.
• The value of CVRs is contingent and uncertain, with no guarantee of any future payment, and they are subordinated to other obligations.
• The company has incurred significant losses since inception, with an accumulated deficit of $302.0 million as of December 31, 2025, and is not currently profitable.
• The company is heavily dependent on the success of RLYB116, which is still in early-stage clinical development, and has no commercialized products or product revenue.

Risks

• Failure to complete, or delays in completing, the proposed Merger with Candid could materially and adversely affect results of operations, business, financial results, and/or stock price.
• The Merger may be completed even if a material adverse effect results from the announcement, industry-wide changes, or other causes.
• Stockholders may not realize a benefit from the Merger commensurate with the ownership dilution experienced.
• Significant additional capital will be required to fund operations if product candidate development continues, and failure to obtain financing could prevent completion of development or commercialization.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to intellectual property or product candidates.
• Failure to meet Nasdaq listing standards could result in delisting, adversely affecting liquidity and market price, and impairing ability to obtain capital.
• Heavy dependence on the success of RLYB116, which is in early-stage clinical development, with high risk of failure.
• Preclinical studies and clinical trials are expensive, time-consuming, difficult to design, and involve uncertain outcomes, potentially leading to additional costs or delays.
• Enrollment and retention of patients in rare disease clinical trials is expensive, time-consuming, and subject to multiple uncontrollable factors.
• Results of preclinical studies, clinical trials, or analyses may not be indicative of later trials, and interim results could differ from final results.
• Product candidates or their administration may cause serious adverse events or undesirable side effects, potentially halting development, delaying/preventing approval, or limiting sales.
• Marketing approval processes are lengthy, time-consuming, and unpredictable; inability to obtain approval would substantially harm the business.
• Market opportunities for rare disease product candidates may be smaller than anticipated, requiring successful patient identification and significant market share for profitability.
• Significant competition from biotechnology and pharmaceutical companies could adversely affect operating results.
• Inability to obtain, maintain, and enforce patent protection for technology and product candidates, or insufficient scope of protection, could allow competitors to commercialize similar products.
• Disruptions in FDA and other government agencies due to funding shortages or global health concerns could hinder timely development or commercialization.
• Inability to establish sales, marketing, and distribution capabilities, either independently or through collaborations, could hinder commercialization.
• Uncertainty regarding potential regulatory developments under the current presidential administration may adversely affect the business.
• Reliance on a central team of limited employees and third parties for administrative, R&D, and other services presents operational challenges.
• Employees and independent contractors may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Reliance on third parties for manufacturing drug substance and product increases risk of insufficient quantities or unacceptable costs.
• System failures, security breaches, or loss of proprietary/confidential information could harm business and operations.
• The market price of common stock may be volatile, leading to substantial losses for investors.
• Insiders have substantial influence over the company, potentially limiting other stockholders' ability to affect key transactions.
• Securities class action litigation is a risk, especially for biotechnology companies.
• No anticipated cash dividends in the foreseeable future, making capital appreciation the sole source of gain.
• Reduced disclosure requirements as an emerging growth company may make common stock less attractive to investors.
• Anti-takeover provisions in corporate documents and Delaware law could discourage acquisitions.
• Designation of Delaware courts as exclusive forum for certain actions could limit stockholders' ability to obtain a favorable judicial forum.
• Risks associated with operating internationally could materially adversely affect the business.
• U.S. federal income tax reform could adversely affect business and financial condition.
• Potential clinical trial or product liability lawsuits could cause substantial liabilities and limit commercialization.
• Unfavorable global economic conditions and geopolitical instability could adversely affect business.

Future Outlook

Rallybio's future outlook is primarily centered on the successful completion of the merger with Candid Therapeutics, which will pivot the combined company's focus to T-cell engager therapeutics for autoimmune diseases. The existing Rallybio pipeline assets will be subject to Contingent Value Rights (CVRs), with efforts to monetize them within one year post-merger. The company anticipates funding operations into 2028, assuming the merger is completed in 2026, but acknowledges the need for significant additional capital if the merger does not proceed.

Management Comments

• Management believes RLYB116 has the potential to demonstrate attributes as a best-in-class therapeutic and, if so, could have a life-transforming impact on patients.
• Management believes RLYB332 has the potential to address a significant unmet need for patients with severe anemia with ineffective red blood cell production or erythropoiesis and iron overload.
• Management believes that an effective, once-weekly, well-tolerated therapy that can be rapidly self-administered with an autoinjector would be an attractive alternative for patients suffering from a wide array of complement mediated diseases.
• Management believes that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months beyond the date of the filing of this Annual Report on Form 10-K, and we anticipate that the proposed merger with Candid will be completed in 2026.

Industry Context

StockSavvy.ai notes that Rallybio's strategic pivot through the merger with Candid Therapeutics reflects a broader trend in the biotechnology sector where smaller, clinical-stage companies facing significant capital requirements and development risks seek strategic transactions to enhance shareholder value and secure funding. The shift from rare disease complement inhibitors to T-cell engager therapeutics for autoimmune diseases indicates a re-prioritization towards a potentially larger or more attractive market segment, while simultaneously attempting to extract value from legacy assets via CVRs. The discontinuation of the RLYB212 program highlights the inherent high-risk nature of drug development, particularly in rare diseases, where clinical efficacy and pharmacokinetic profiles are critical hurdles. The concurrent financing of over $500 million for Candid underscores the strong investor appetite for promising assets in the autoimmune space, especially those leveraging advanced therapeutic modalities like TCEs.

Comparison to Industry Standards

• RLYB116, a C5 inhibitor, aims to compete in a market with established antibody-based C5 inhibitors like Soliris and Ultomiris. Rallybio's strategy emphasizes a once-weekly, small volume, subcutaneous injection via autoinjector, which could offer a significant patient-friendly advantage over existing intravenous or daily injection therapies, potentially positioning it as a 'best-in-class' option if clinical benefits are confirmed.
• The discontinuation of the RLYB212 program for FNAIT prevention, based on PK data failing to meet target concentrations, is a common occurrence in early-stage drug development, reflecting the high attrition rate of drug candidates across the industry. This decision aligns with industry best practices of halting programs that do not meet critical efficacy thresholds to conserve capital.
• The merger with Candid Therapeutics, a clinical-stage company focused on T-cell engager (TCE) therapeutics for autoimmune diseases, positions Rallybio in a highly competitive and rapidly evolving therapeutic area. TCEs are a cutting-edge modality, and success will depend on Candid's ability to differentiate its portfolio against other companies developing similar advanced therapies for autoimmune conditions.
• The use of Contingent Value Rights (CVRs) to monetize legacy assets is a common mechanism in biotech mergers, allowing the acquiring company to focus on its core pipeline while providing existing shareholders with potential future upside from divested or deprioritized programs, similar to deals seen with companies like Pfizer or Bristol Myers Squibb in their acquisition strategies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation or legal proceedings that are probable to have a material adverse effect on its business. However, litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, and reputational harm.

Related Party Transactions

• Robert Hopfner, a current member of the board, is affiliated with an investment fund participating in the Concurrent Financing related to the merger with Candid Therapeutics.
• Dr. Mackay, Chairman of the Board, is party to a consulting agreement with the Company, effective January 1, 2025, at a rate of $18,750 per month ($225,000 for the full year).

Stakeholder Impact

• **Shareholders (Pre-Merger Rallybio):** Will experience significant dilution (expected to own ~3.65% of combined company) but will receive CVRs for potential future proceeds from legacy assets. The stock price may be volatile based on merger completion and CVR value uncertainty.
• **Shareholders (Candid & Concurrent Financing Investors):** Will become the dominant owners of the combined company (~96.35%), benefiting from the new capital infusion and the strategic pivot to Candid's T-cell engager pipeline.
• **Employees:** Workforce reductions in February 2024 (45% of positions) and May 2025 (40% of positions) have occurred, impacting employee morale and potentially the ability to retain key personnel. Remaining employees are crucial for merger consummation and CVR monetization.
• **Customers/Patients:** The discontinuation of the RLYB212 program means patients seeking FNAIT prevention will not have this therapy from Rallybio. RLYB116 and RLYB332 programs continue, offering potential future therapies for complement dysregulation and iron overload, respectively.
• **Suppliers/CMOs:** Continued reliance on third-party CMOs for manufacturing, with potential risks of supply disruption or non-compliance with cGMP regulations.
• **Creditors:** CVRs are unsecured and subordinated to all current or future senior obligations of the combined company, indicating lower priority for CVR holders in case of financial distress.

Next Steps

• Complete the proposed Merger with Candid Therapeutics, Inc. in 2026.
• Rallybio will use commercially reasonable efforts for one year after the Closing Date to effect the disposition of its Legacy Assets.
• Recursion Pharmaceuticals, Inc. is eligible to receive a $5.0 million milestone payment upon initiation of dosing in a Phase 1 clinical study for REV102.
• Rallybio anticipates requesting PRIME designation for certain product candidates in the future.
• The new EU pharmaceutical legislation (Pharma Package) is anticipated to be fully applicable in 2028.
• The Biotech Act introduces a 12-month extension to the Supplementary Protection Certificate (SPC) for advanced therapy medicinal products and innovative biotech medicines, aiming to incentivize EU-based manufacturing and R&D.

Key Dates

Recommendation

The proposed merger with Candid Therapeutics represents a significant strategic shift for Rallybio, offering a potential lifeline through a substantial capital infusion and a pivot to a new, promising pipeline. However, existing Rallybio shareholders face extreme dilution and the value of the CVRs for legacy assets is highly uncertain. While the RLYB116 program shows promise, the discontinuation of RLYB212 highlights the inherent risks. The stock is currently a 'hold' due to the speculative nature of the CVRs and the execution risk associated with integrating the merger and advancing Candid's pipeline, balanced against the potential for long-term value creation if the new strategy is successfully implemented.

Keywords

Biotechnology, Clinical-stage, Merger, Candid Therapeutics, RLYB116, C5 inhibitor, Complement dysregulation, Rare diseases, Contingent Value Rights, Legacy Assets, RLYB332, MTP-2 antibody, Iron overload, Preclinical development, SEC filing, 10-K, Financial results, Nasdaq compliance, Reverse stock split, Drug development, Clinical trials, Regulatory approval, Intellectual property, Biopharma, Autoimmune diseases, T-cell engager, Recursion Pharmaceuticals, ENPP1 inhibitor, Hypophosphatasia, FNAIT, Johnson & Johnson, AbCellera